Novartis Investigative Site

Eaubonne 95600

0 studies enrolling now · 2 studies all time

What they study most

Cytokine Storm (Covid-19), Heart Failure With Reduced Ejection Fraction (HF-rEF)

Studies at this site

• Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm — Completed
• Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF) — NO_LONGER_AVAILABLE